Insmed’s bronchiectasis treatment in development offers an opportunity for investors, according to RBC Capital Markets. Analyst Leonid Timashev initiated coverage of the biopharmaceutical stock at an outperform rating. Timashev set a $100 price target, which suggests upside of 25% over where the stock finished Monday. “While shares have continued to do well in the face of pressure on the sector, we still see additional value to be unlocked in the second half of the year, and we would be buyers,” Timashev told clients in a Monday note. Key to this call is Brensocatib, the company’s investigational treatment for bronchiectasis. Timashev said this offering may amount to a $6.5 billion opportunity and have a rapid launch given the high likelihood of regulatory approval. With momentum, he said the drug could see a peak sales opportunity of $8.2 billion. “We believe the brensocatib launch is likely to be among the strongest launches in 2025,” Timashev said. That’s “driven by significant patient and physician demand on the backdrop of a disease with no effective treatment options.” Timashev went on to describe Brensocatib as a “pipeline in a product.” He also listed other drugs in development like Arikayce for lung disease that can help deliver value. The bull camp on the stock is large. Every other analyst on Wall Street covering the stock has a buy rating, according to LSEG. Shares have jumped nearly 16% since 2025 began. That builds on the prior year’s rally of more than 122%.
Buy this biopharmaceutical stock that can rally 25%, says RBC Capital Markets
